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OBJECTIVE
Fibroblast growth factor 21 (FGF21) is involved in the regulation of energy balance
and adipose metabolism. Our previous genome-wide association study identiﬁed
genetic variants in the FGF21 region associated with macronutrient intake prefer-
ence. We investigated whether the FGF21 genotype modiﬁed effects of weight-loss
diets varying inmacronutrient intake on changes in adiposity in a 2-year randomized
diet intervention trial.
RESEARCH DESIGN AND METHODS
We genotyped FGF21 rs838147 in 715 overweight or obese individuals who were
assigned to one of four diets varying in macronutrient contents. A DEXA scan was
performed to evaluate body composition.
RESULTS
We observed a signiﬁcant interaction between the FGF21 genotype and carbohydrate/
fat intake on 2-year changes in waist circumference (WC), percentage of total fat
mass, and percentage of trunk fat (P = 0.049, P = 0.001, and P = 0.003 for interac-
tion, respectively). In response to the low-carbohydrate/high-fat diet, carrying the
carbohydrate intake–decreasing C allele of rs838147 was marginally associated
with less reduction inWC (P = 0.08) and signiﬁcantly associated with less reduction
of total fat mass (P = 0.01) and trunk fat (P = 0.02). Opposite genetic associations
with these outcomes were observed among the high-carbohydrate/low-fat diet
group; carrying the C allele was associated with a greater reduction of WC, total
body fat mass, and trunk fat.
CONCLUSIONS
Our data suggest that FGF21 genotypes may interact with dietary carbohydrate/
fat intake on changes in central adiposity and body fat composition. A low-calorie,
high-carbohydrate/low-fat diet was beneﬁcial for overweight or obese individuals
carrying the carbohydrate intake–decreasing allele of the FGF21 variant to im-
prove body composition and abdominal obesity.
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Macronutrients, including fat, carbohy-
drate, and protein, are primary sources
of energy and play a central role in de-
termining energy balance, which regu-
lates body fat accumulation and weight
reduction (1,2). In our recent genome-
wide association studies (GWAS), we
identiﬁed sequence polymorphisms
close to the ﬁbroblast growth factor
21 (FGF21) gene that were associated
with intakes of macronutrients (3,4).
Our studies consistently showed that
the genetic variation in the FGF21 re-
gion was associated with carbohydrate
or fat intake (3,4). Prior studies reported
that circulating levels of FGF21 in-
creased in response to carbohydrate in-
take (5,6), and more recent studies
provided possible mechanisms for the
role of FGF21 in regulating “sweet taste
preference” (7–9).
FGF21 has been attracting great inter-
est as a whole-body metabolic regulator
of energy balance and adipose metabo-
lism (10,11) and also as a therapeutic
potential for treatment of obesity (10).
Several studies found that elevated
blood concentrations of FGF21 were
positively correlated with BMI (12–16),
waist circumference (WC) (12,14,16,17),
fat mass (13,16), or visceral adipose area
(18,19), suggesting obesity as a FGF21-
resistant state (20). A study also showed
a signiﬁcant association between circulat-
ing FGF21 levels and fasting-mediated
weight loss in healthy subjects (21).
Although compelling evidence has
shown that dietary interventions with
modiﬁcations of macronutrients may
promote weight loss and improve body
fat distribution (2,22,23), considerable
interindividual variance has long been
noted in response to dietary interven-
tions, and genetic variations may at
least partly account for such variance. We
hypothesized that the macronutrients-
associated FGF21 genotype might
modify the effects of dietary interven-
tions varying in macronutrient intakes
on changes in adiposity and body com-
position. The Preventing Overweight Us-
ing Novel Dietary Strategies (POUNDS)
Lost trial is thus far one of the largest
randomized intervention trials comparing
diets varying in macronutrients on long-
term weight loss (24). In this study, we
investigatedwhether theGWAS-identiﬁed
macronutrient intake–associated variant
in the FGF21 gene modiﬁed effects of
weight-loss diets on the improvement of
adiposity and body composition in the
POUNDS Lost trial.
RESEARCH DESIGN AND METHODS
Study Participants
The POUNDS Lost trial was conducted
from October 2004 through December
2007 at two sites: Harvard T.H. Chan
School of Public Health and Brigham
and Women’s Hospital in Boston, MA,
and the Pennington Biomedical Re-
search Center of Louisiana State Univer-
sity System in Baton Rouge, LA. Details
of the study have been described pre-
viously (24). Brieﬂy, this study included
811 overweight or obese individuals
who were randomly assigned to one of
four energy-reduced diets varying in
macronutrient compositions of fat, pro-
tein, and carbohydrate to compare their
effects on body weight change during a
2-year follow-up time. The targeted per-
centages of energy derived from fat,
protein, and carbohydrates in the four
diets were 1) 20, 15, and 65%; 2) 20, 25,
and 55%; 3) 40, 15, and 45%; and 4) 40,
25, and 35%, respectively. Thus, two di-
ets were low fat (20%), and the other
two diets were high fat (40%); two diets
were average protein (15%), and the
other two diets were high protein
(25%), which constituted a two-by-two
factorial design. The low-fat/high-fat diets
were the same as the high-carbohydrate/
low-carbohydrate diets in the POUNDS
Lost Study. The low-carbohydrate/
high-fat diet was indicated by 35% or
45% carbohydrate/40% fat of energy; the
high-carbohydrate/low-fat diet was indi-
cated by 55% or 65% carbohydrate/20%
fat of energy in this study. The study was
approved by the human subjects com-
mittee at each institution and by a data
and safety monitoring board appointed
by the National Heart, Lung, and Blood
Institute. All participants gave written
informed consent.
In the current study, we investigated
the data of 715 overweight or obese in-
dividuals (mean age 50.9 [SD 9.3] years)
who had genotyping data on the FGF21
variant rs838147 at the baseline exami-
nation. Of the study participants, 573
(80%) were white, 106 (15%) were Afri-
can American, 25 (3%) were Hispanic,
and 11 (22%) were Asian or other ethnic
groups by self-report. WC data were
available for 639 individuals at 6 months
and for 541 at 2 years. For the assess-
ment of body composition, a random
sample of ;50% of the total study par-
ticipants were selected to undergo
DEXA scans for fat mass and lean mass
at baseline and after 6 months and
2 years of randomization (25). The
DEXA scan was performed in 373 at
the baseline examination, in 297 at
6 months, and in 211 at 2 years.
Measurements
Body weight and WC were measured at
baseline, 6, 12, and 18 months, and
2 years. Height was measured at the
baseline examination. BMI was calcu-
lated as weight in kilograms divided by
the square of height in meters (kg/m2).
The DEXA scan was performed using a
Hologic QDR 4500A (Hologic, Inc.) after
an overnight fast. Total fat mass, total
lean mass, whole-body total percentage
fat mass, and trunk fat percentage were
measured at baseline, 6 months, and 2
years of follow-up. Dietary intake was as-
sessed in a random sample of 50% of the
total participants by a review of 5-day
diet records at baseline and by 24-h recall
during a telephone interview on 3 non-
consecutive days at 6 months and at
2 years to assess the adherence to the
dietary intervention program.
Genotyping
DNA was extracted from the buffy coat
fraction of centrifuged blood using the
QIAamp Blood Kit (Qiagen). Our previ-
ously reported single-nucleotide poly-
morphism (SNP) in the FGF21 locus
rs838147 was genotyped (3). Genotyp-
ing was performed using the OpenArray
SNP Genotyping System (BioTrove). The
C allele of the rs838147 was associated
with lower carbohydrate intake (3). The
genotype success rate was 99%. The ge-
notype frequencies were in Hardy-
Weinberg equilibrium among all study
participants or among two major (white
and African American) ethnic groups
(P . 0.05).
Statistical Analysis
General linear models for continuous
variables and x2 test for categorical var-
iables were performed for comparison
of characteristics across the genotype
at baseline examination. The primary
outcomes were changes (D) in body
weight, WC, and body composition as-
sessed by DEXA (total fat, total lean, to-
tal fat mass percentage, and trunk fat
percentage) among participants who re-
mained in the trial. General linear models
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were used to compare changes from
baseline in these outcomes across geno-
type groups according to low- or high-
carbohydrate diet group at 6-month and
2-year visits with an adjustment of age,
sex, ethnicity, and baseline value for the
respective outcome (model 1). We also
analyzed data with BMI at the baseline
examination being further included in
the adjusted model (model 2). Additive
genetic models were used in the analysis.
To test potential gene–diet interactions,
a genotype-by-diet product term (e.g.,
FGF21genotype3high-/low-carbohydrate
diet group) was included in the models.
We also performed similar analyses only
among white participants. We per-
formed an additional analysis using lin-
ear mixed model with time variable as
a repeated measurement factor. We
tested genetic associations with the tra-
jectory of changes in WC and body com-
position over the 2-year intervention by
including genotype–time interaction
terms. Statistical analyses were per-
formed with SAS 9.3 software (SAS Insti-
tute Inc.). The statistical signiﬁcance was
considered for P , 0.05.
RESULTS
The frequency of the FGF21 rs838147
carbohydrate intake–decreasing C allele
was 44.8% among the study partici-
pants. The genotype distribution did
not differ by sex or the carbohydrate
diet interventions, whereas a signiﬁcant
difference was observed across ethnic-
ity (P, 0.001). No signiﬁcant difference
was found in age, BMI, bodyweight,WC,
and body composition according to the
FGF21 rs838147 genotype (Table 1) at
the baseline examination; however,
the C allele was positively correlated
with total energy intake (P = 0.02). We
did not observe signiﬁcant main associ-
ations of the FGF21 genotype with
changes in body weight, WC, or body
composition (total fat, total lean, total
fat mass percentage, or trunk fat per-
centage) during the 2-year intervention
after adjustment for age, sex, ethnicity,
BMI at baseline, low-/high-carbohydrate
diet group, and baseline value for the
respective outcome (P . 0.05 for all
the outcomes, data not shown).
We found signiﬁcant interactions
between the genotype and low-/high-
carbohydrate diet on 2-year changes in
WC, total fat, total lean, total fat mass
percentage, and trunk fat percentage
(Pinteraction = 0.049, 0.004, 0.003, 0.001,
and 0.003, respectively, inmodel 1) (Table
2). In response to the low-carbohydrate
diet, an increasing number of the C allele
of the FGF21 variant was signiﬁcantly as-
sociated with an increase in WC, total fat,
total fat mass percentage, and trunk fat
percentage at 2 years. Conversely, carry-
ing the C allele was negatively associ-
ated with changes in these outcomes in
response to the high-carbohydrate diet
(Table 2 andFig. 1). Additional adjustment
of BMI at the baseline inmodel 2 slightly
attenuated the association, although
Table 1—Characteristics of study participants at the baseline examination
according to the FGF21 genetic variant rs838147
TT TC CC
n = 211 n = 367 n = 137 P value
Age, years 50.6 (9.1) 51.1 (9.4) 50.9 (9.4) 0.76
Male sex 75 (35.6) 147 (40.1) 57 (41.6) 0.44
Race or ethnic group ,0.001
White 150 (71.1) 306 (83.4) 117 (85.4)
Black 50 (23.7) 42 (11.4) 14 (10.2)
Hispanic or other 11 (5.2) 19 (5.2) 6 (4.4)
Diet group 0.28
Low carbohydrate 114 (54.0) 173 (47.1) 68 (49.6) d
High carbohydrate 97 (46.0) 194 (52.9) 69 (50.4) d
Dietary intake per day*
Energy, kcal 1,892 (545) 1,976 (555) 2,099 (617) 0.02
Protein, % 18.3 (2.9) 18.1 (3.6) 17.6 (2.9) 0.27
Fat, % 37.7 (6.3) 36.8 (5.9) 36.4 (5.9) 0.16
Carbohydrate, % 43.9 (7.3) 44.7 (7.8) 45.5 (7.9) 0.17
BMI, kg/m2 32.6 (3.8) 32.8 (3.8) 32.5 (4.1) 0.997
Body weight, kg 92.2 (14.5) 93.7 (15.9) 94.1 (16.6) 0.24
WC, cm 102.3 (12.7) 104.4 (12.9) 103.8 (13.9) 0.19
Body composition data**
Whole-body fat, kg 34.4 (7.9) 35.3 (7.6) 35.9 (8.5) 0.20
Whole-body lean, kg 58.7 (12.6) 61.0 (13.3) 61.4 (14.2) 0.14
Whole-body fat mass, % 37.1 (7.0) 36.9 (6.7) 37.1 (7.3) 0.96
Trunk fat, % 38.0 (6.1) 38.1 (5.8) 38.1 (6.5) 0.87
Data are mean (SD) or n (%). *Data for dietary intake per day were available for 366 individuals
across the three genotype groups: TT, n = 111; TC, n = 194; and CC, n = 61. **Data for body
composition were available for 373 individuals across the three genotype groups: TT, n = 113; TC,
n = 189; and CC, n = 71.
Table 2—Effect of the FGF21 genetic variant on changes in body weight, WC, and
body composition in response to low- or high-carbohydrate diet at 2 years of diet
intervention
Low carbohydrate High carbohydrate
Pinteractionb (SE) P b (SE) P
Model 1
DBody weight, kg 1.46 (0.62) 0.02 20.16 (0.64) 0.8 0.07
DWC, cm 1.22 (0.69) 0.08 20.66 (0.66) 0.32 0.049
DTotal fat, g 1,861 (849) 0.03 21,319 (781) 0.09 0.004
DTotal lean, g 837 (420) 0.049 2799 (410) 0.054 0.003
DTotal fat mass, % 1.25 (0.49) 0.01 20.95 (0.50) 0.06 0.001
DTrunk fat, % 1.52 (0.65) 0.02 21.12 (0.64) 0.08 0.003
Model 2
DWC, cm 1.16 (0.68) 0.09 20.44 (0.65) 0.5 0.09
DTotal fat, g 1,848 (854) 0.03 21,221 (786) 0.12 0.006
DTotal lean, g 853 (421) 0.046 2806 (414) 0.054 0.003
DTotal fat mass, % 1.21 (0.49) 0.02 20.94 (0.5) 0.06 0.002
DTrunk fat, % 1.35 (0.66) 0.04 21.08 (0.64) 0.09 0.006
b represents changes in outcomes for the increasing number of C allele of the SNP rs838147.
Bold values indicate statistical signiﬁcance (P, 0.05). Model 1: age, sex, ethnicity, and variable
of interest at the baseline examination. Model 2: model 1 plus BMI at the baseline examination.
care.diabetesjournals.org Heianza and Associates 1911
P values for interactions between geno-
type and the low-/high-carbohydrate diet
in 2-year changes of body composition
remained signiﬁcant. Further adjustment
for total energy intake at baseline did not
appreciably change the results (data not
shown). When the analysis was per-
formed only among white individuals,
we observed fundamentally similar results
with signiﬁcant interactions for 2-year
changes in total fat, total lean, total fat
mass percentage, and trunk fat percent-
age (all Pinteraction, 0.05 in model 2).
We also performed linear mixedmod-
els integrating measures at 6 months
and 2 years to assess the trajectory of
genetic associations with the outcomes
across the course of dietary intervention
(Fig. 2). On the one hand, the gene–diet
interaction patterns on WC were con-
sistent at 6 months and 2 years, but
participants regained WC during the
6 months and 2 years (Fig. 2A and B).
On the other hand, we observed signif-
icant genotype–time interactions, par-
ticularly for changes in total fat mass
percentage and trunk fat percentage
among the low-carbohydrate diet group
(Fig. 2C and E) and the high-carbohydrate
diet group (Fig. 2D and F) over the 2-year
trajectories. Results of genotype–time
interactions were signiﬁcant even after
adjustment for age, sex, ethnicity, BMI,
and the values for the respective out-
come traits at the baseline examination;
the genetic associations with improving
in body fat composition appeared to be
more pronounced at 2 years than at
6 months (Fig. 2C–F). Particularly, in
the low-carbohydrate diet group, indi-
viduals without C allele (Fig. 2C and E,
dotted line) continued to lose total fat
mass and trunk fat from 6 months to
2 years.
CONCLUSIONS
In this trial, one of the largest randomized
dietary intervention trials on weight loss,
we found that the macronutrient intake–
associated FGF21 genotype signiﬁcantly
interacted with dietary carbohydrate/fat
intake on changes in central adiposity
and body composition. In response to
the low-carbohydrate/high-fat diet, an
increasing number of the carbohydrate
intake–decreasing C allele of rs838147
was associated with less reduction in
WC, whole-body fat, or trunk fat. Con-
versely, opposite genetic effects on these
outcomes were observed in response to
the high-carbohydrate/low-fat diet; car-
rying the C allele was associated with a
greater reduction of WC, whole-body fat,
and trunk fat.
Our ﬁndings are in line with the biolog-
ical roles of FGF21 in regulating body ad-
iposity and dietary intake. The FGF21
gene encodes FGF21, a circulating hor-
mone-like protein with pleiotropic meta-
bolic actions, such as regulating glucose
and fatmetabolism, andeffect on reducing
body weight (26). On the one hand, ele-
vated circulating levels of FGF21 have
been associated with a variety of adiposity
measures such as WC (12,14,16,17), BMI
(12–16), fat mass (13,16), and visceral fat
(18,19), with obesity considered an FGF21-
resistant state (20). On the other hand,
several studies in rodents and humans re-
ported that FGF21 levels were inﬂuenced
by dietary intake of fat, carbohydrate, or
protein (5,6,27–31). In two recent GWAS
(3,4), we identiﬁed the genetic variants in
the region of the FGF21 gene that were
associated with dietary macronutrient in-
takes, and rs838147 showed the strongest
association with carbohydrate intake. In
the current study, we observed signiﬁcant
interactions between the FGF21 genotype
and carbohydrate intakeonadipositymea-
surements. The results from the present
study and previous GWAS consistently
indicate that FGF21 may play a role in reg-
ulating metabolisms of dietary carbohy-
drate. Because low-carbohydrate intake
is usually accompanied by high-fat intake,
we could not determinewhether carbohy-
drate or fat would best explain our ﬁnd-
ings. Nonetheless, two recent studies
found that FGF21 acted on the brain to
regulate carbohydrate or sweet taste
and did not affect response to fat taste
preference (7,8), also suggesting that the
FGF21 genetic variants might primarily in-
teract with dietary carbohydrate intake on
adiposity measures.
In addition, we found that the genetic
effects were opposite according to die-
tary carbohydrate intake on improving
adiposity measurements. Such an oppo-
site genetic effect could be partly ex-
plained by the “differential susceptibility
hypothesis,” (32–34) a theory that sug-
gests that genes may be conceptualized
as “plastic,” because genetic risk can be
modiﬁed by environmental factors, such
as dietary factors. Some individuals might
bemore affected by environmental expo-
sures because of genetic make-up in a
for-better-and-for-worse manner, de-
pending on the environment to which
they are exposed (33). We observed that
carriers of the carbohydrate-decreasing
allele showed an opposite response to
diet interventions varying in carbohy-
drate intake; we assume that high- or
low-carbohydrate intake may differen-
tially modulate the function or activity
of the FGF21 genewith the variant allele.
Further studies are warranted to test
such postulations.
We also observed signiﬁcant gene–
diet interactions, particularly on body
fat composition and marginally on WC.
Previous studies suggested that FGF21
Figure 1—Changes in WC (A), total fat mass
percentage (B), and trunk fat percentage (C)
according to the FGF21 genetic variant
rs838147 and low- or high-carbohydrate diet
at 2 years of diet intervention (white bars,
FGF21 rs838147 TT genotype; gray bars, TC
genotype; black bars, CC genotype). Data are
means 6 SE values after adjustment for age,
sex, ethnicity, and BMI at the baseline exam-
ination and value for the respective outcome
traits at the baseline examination. CHO,
carbohydrate.
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may act directly on adipose tissue and
that the weight-reducing effect of
FGF21 may be partially mediated by in-
duction of thermogenesis in adipose tis-
sue and browning of white adipose
tissue (11,26,35). A study has demon-
strated that FGF21 levels were slightly
better correlated with WC than with
BMI and that WC was signiﬁcantly posi-
tively associated with serum FGF21 lev-
els even after adjustment for BMI (12).
Plasma concentrations of FGF21 were
also reported to be positively associated
with both BMI and fat mass, whereas
only body fat mass was predictive of
plasma FGF21 concentrations when
the analysis adjusted for covariates
(13). Taken together, these data suggest
that the FGF21 genotype may particu-
larly affect certain body fat composition,
independent of overall body weight.
Whether changes in energy expenditure
contribute to explaining our results
would need to be further investigated.
Intriguingly, our analysis using the lin-
ear mixed models indicated signiﬁcant
genotype–time interaction, supporting
that the gene–diet interaction became
stronger at 2 years than at 6 months. Par-
ticipants in the POUNDS Lost trial regained
bodyweight from 6months to 2 years (24).
Nonetheless, we found that carriers with-
out the C allele in the low-carbohydrate/
high-fat diet group continued to lose total
body fat and trunk fat even though they
regained body weight and WC from
6 months to 2 years. Although the mecha-
nisms underlying such observations re-
mained unclear, our data suggest that
different pathways might be involved in
linking FGF21 to overall body weight and
speciﬁc body fat composition. Because
FGF21 has diverse metabolic functions in
multiple target organs, including liver and
brain (26,36–38), further investigations are
warranted to verify our postulations.
To the best of our knowledge, this is
the ﬁrst study to show signiﬁcant inter-
actions between the macronutrient
intake–associated FGF21 genetic variation
and dietary carbohydrate/fat intake on
improvement of body composition and
central obesity in a large and long-term
randomized trial among overweight or
obese individuals. Growing evidence
shows that FGF21 may be a potential
for the treatment of obesity-related
metabolic diseases (10,37–39); our
study provides novel data to support po-
tential precision dietary interventions
considering the FGF21 genotype.
Nonetheless, several limitations of this
study should also be considered. We did
not measure circulating FGF21 concentra-
tions in this study,which limitedour ability
to explore potential underlying mecha-
nisms. In addition, 80% of our study par-
ticipants were white, and the genotype
distribution differed across ethnicities.
Our subgroup analysis in whites showed
similar results; nevertheless, whether our
ﬁndings are generalizable to other ethnic-
ities needs to be further investigated.
In conclusion, our study showed that
dietary carbohydrate/fat intake modi-
ﬁed the effect of the FGF21 genotype
on changes in central adiposity and
body fat composition among over-
weight or obese individuals during a
2-year dietary intervention. Our ﬁndings
suggest that a high-carbohydrate/low-
fat diet may be beneﬁcial for overweight
Figure 2—Trajectories of WC (A and B), total body fat mass percentage (C and D), and trunk fat
percentage (E and F) according to FGF21 variant rs838147 in response to low- or high-carbohydrate
diet during the 2-year intervention assessment (black circle and solid line, CC genotype; gray circle
and gray solid line, TC genotype; white circle and dotted line, TT genotype). Data are mean6 SE
after adjustment for age, sex, ethnicity, BMI at the baseline examination, and value for the
respective outcome traits at the baseline examination. P for interaction (genotype 3 time)
after adjustment for age, sex, ethnicity, and BMI at the baseline examination: P . 0.05 (not
signiﬁcant) for A and B; P , 0.001 for C, D, E, and F. P for interaction (genotype 3 time) after
adjustment for age, sex, ethnicity, BMI, and value for the respective outcome traits at the
baseline examination: P. 0.05 (not signiﬁcant) for A and B; P = 0.006 for C; P = 0.01 forD and E;
and P = 0.02 for F.
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or obese individuals who carry the car-
bohydrate intake–decreasing allele of
the FGF21 variant to improve body fat
composition and abdominal obesity.
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